‘Another benefit’: The pill shown to reduce ovarian cancer risk Australian research finds the oral contraceptive pill can reduce risk of the cancer by 26% among women who have used it at any age.
OCP pharmacy pilot announced for WA While the RACGP does not support pharmacy prescribing, its place on the working group is an opportunity to minimise risk.
Study questions Paxlovid’s COVID-19 ‘usefulness’ Researchers say the antiviral does little to reduce symptom duration for some vaccinated patients, but still recommended its use for the vulnerable.
Tighten Paxlovid eligibility: PBAC advice The committee that looks at PBS listings has recommended the first-line COVID-19 treatment be limited to the highest risk patients aged 50–69 years.
GPs’ role in early detection of oral cancer now easier A new CPD activity aims to upskill GPs in prevention counselling, early identification and referral pathways for the cancer.
Anti-inflammatory could boost emergency contraceptive: Study Researchers have called for further work into what they have called the ‘really exciting’ findings of a trial undertaken in Hong Kong.
GP support for changes that would help end ‘cycle of poverty’ An RACGP submission has recommended several initiatives aimed at improving access to dental care.
Confusion over UTI pharmacy prescribing ethics approval The NSW pharmacy prescribing trial is still yet to be registered with ANZCTR, despite its first phase having already begun.
More than 1000 pharmacies registered for prescribing trial The clinical trial was originally due to begin in April but issues with ethics approval reportedly resulted in it being delayed.
Wider eligibility for Paxlovid announced From 1 April the availability of the oral antiviral on the PBS will expand to include over-60s with only one risk factor for severe disease.